Haloalkyl containing compounds as cysteine protease inhibitors

A compound of Formula (I):

• wherein:
• R1 and R2 taken together with the carbon atom to which both R1 and R2 are attached form (i) cycloalkylene optionally substituted with one or two Rb independently selected from alkyl or halo or (ii) heterocyclylalkylene optionally substituted with one to four Rc independently selected from alkyl or halo or optionally substituted with one to three Rc where two Rc are independently selected from alkyl, halo, haloalkyl, or hydroxyl and the third Rc is hydroxyalkyl, alkoxyalkyl, alkoxyalkyloxyalkyl, aryloxyalkyl, heteroaryloxyalkyl, aminoalkyl, acyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, cycloalkyl, cycloalkylalkyl, —S(O)n2R14, -alkylene-S(O)n2—R15, —COOR16, -alkylene-COOR17, —CONR18R19, or -alkylene-CONR20R21 (where n2 is 0-2 and R14-R17, R18 and R20 are independently hydrogen, alkyl, haloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, cycloalkylalkyl, or heterocyclyl and R19 and R21 are independently hydrogen or alkyl) wherein the aromatic or alicyclic ring in the groups attached to heterocyclylalkylene is optionally substituted with one, two, or three substituents independently selected from alkyl, haloalkyl, alkoxy, hydroxy, haloalkoxy, halo, carboxy, alkoxycarbonyl, amino, monosubstituted amino, disubstituted amino, or acyl;
• R3 is hydrogen;
• R4 is cycloalkylalkyl, aralkyl, heteroaralkyl, heterocyclylalkyl, or -alkylene-X1—R22 [wherein X1 is —NR23—, —O—, —S(O)n3—, —CO—, —COO—, —OCO—, —NR23CO—, —CONR23—, —NR23SO2—, —SO2NR23—, —NR23COO—, —OCONR23—, —NR23CONR24—, or —NR23SO2NR24— (where each R23 and R24 are independently hydrogen, alkyl, or acyl and n3 is 0-2) and R22 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, or heterocyclylalkyl] wherein said alkylene chain in -alkylene-X1—R22 is optionally substituted with one to six halo and the aromatic or alicyclic ring in R4 is optionally substituted with one, two, or three Rd independently selected from alkyl, haloalkyl, alkoxy, hydroxy, haloalkoxy, halo, nitro, cyano, carboxy, alkoxycarbonyl, aryl, heteroaryl, cycloalkyl, cycloalkylalkyl, aralkyl, heteroaralkyl, amino, monosubstituted amino, disubstituted amino, or acyl;
• or
• R3 and R4 together with the carbon atom to which they are attached form cycloalkylene;
• R5 is hydrogen;
• R6 is -haloalkylene-X2—R25 [wherein X2 is —O— or SOn4— where n4 is 0-2 and R25 is alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl] wherein the aromatic or alicyclic ring in R25 is optionally substituted by one, two, or three Re independently selected from alkyl, halo, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, haloalkyl, haloalkoxy, cyano, nitro, acyl, aryl, aryloxy, arylsulfonyl, heteroaryl, heteroaryloxy, heteroarylsulfonyl, heterocyclyl, heterocyclyloxy, cycloalkyl, cycloalkyloxy, carboxy, alkoxycarbonyl, alkylsulfonyl, aminosulfonyl, or aminoalkyl;
• and
• R7 is alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl attached to the carbon atom substituted with the R7 group via a carbon-carbon single bond;
• wherein the aromatic or alicyclic ring in R7 is optionally substituted with one, two, or three Rg independently selected from alkyl, halo, haloalkyl, hydroxy, alkoxy, haloalkoxy, alkylsulfonyl, carboxy, alkoxycarbonyl, aminosulfonyl, hydroxyalkyl, aminocarbonyl, aminoalkyl, alkoxyalkyl, cyano, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, or heterocyclylalkyl and further wherein the aromatic or alicyclic ring in Rg is optionally substituted with one, two, or three Rh independently selected from alkyl, halo, haloalkyl, alkoxy, cycloalkyl, monosubstituted amino, disubstituted amino, aminocarbonyl, acyl, carboxy, alkoxycarbonyl, alkylthio, alkylsulfonyl, aminosulfonyl, arylsulfonyl, heteroaryl, heteroarylsulfonyl, heterocyclyl, heterocyclylsulfonyl, hydroxyalkyl, or alkoxyalkyl;
• or
• a pharmaceutically acceptable salt thereof.